AI drug discovery
From drug discovery to forecasting kidney disease AI could be the next game-changer in healthcare.
The company plans to use this money to use its therapeutics program in human clinical trials.
The deep learning framework proposed by Ping An learns molecular representations from large volumes of unlabelled molecules.
The partners will use a new method of training AI known as transformer neural networks.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
Also: Vocalis Health and Mayo Clinic seek new pulmonary hypertension biomarkers; Sensyne Health and Microsoft's strategic partnership focuses on clinical AI co-development.
insitro unveiled a $143 million Series B round on the same day that fellow machine learning company Exscientia highlighted its own $60 million Series C raise.